# US 2023/0417767 A1 · Compositions and methods for the diagnosis and treatment of age-related macular degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0417767 A1
- Document ID: US20230417767A1
- Status: Published application
- Kind: A1
- Application number: 18/138,058
- Filed: 2023-04-22
- Published: 2023-12-28
- Earliest claimed: 2016-02-06
- Assignees: Georgetown University
- Applicants: Georgetown University
- Inventors: Nady Golestaneh
- Web page: https://patentgrep.com/patent/US20230417767A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4245: Oxadiazoles
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5023: {on expression patterns}
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/91142: Pentosyltransferases (2.4.2)
- G01N 2333/978: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- G01N 2800/164: Retinal disorders, e.g. retinopathy
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) polymerase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-Iα) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-Iα or AKT3 and/or higher acetylation levels of PGC-Iα in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.

## Claims

### Claim 1

A method of determining if a subject is at risk of developing dry age-related macular degeneration (dry AMD), the method comprising
a) determining expression or activity levels of at least one of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α), NAD-dependent deacetylase sirtuin-1 (SIRT-1), and Poly (Adenosine diphosphate-Ribose) Polymerase 2 (PARP2) in a sample obtained from the subject; or determining mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3) in a sample obtained from the subject,
b) comparing the determined expression or activity levels of PGC-1α or SIRT-1 or PARP2 in the subject with the expression or activity levels obtained from subjects determined to define normal expression or activity levels of PGC-1α or SIRT-1 or PARP2 to determine if the subject's expression or activity levels of PGC-1α or SIRT-1 or PARP2 are altered compared to normal expression or activity levels of PGC-1α or SIRT-1 or PARP2; or comparing the determined mRNA levels of AKT3 in the subject with the mRNA levels obtained from subjects determined to define normal mRNA levels of AKT3 to determine if the subject's mRNA levels of AKT3 are altered compared to normal mRNA levels of AKT3,
wherein a reduction in the expression or activity levels of PGC-1α or SIRT-1 in the sample compared to normal levels is indicative that the subject is at risk of developing dry AMD; an increase in the expression or activity levels of PARP2 in the sample compared to normal levels is indicative that the subject is at risk of developing dry AMD; and a reduction in the mRNA levels of AKT3 in the sample compared to normal mRNA levels is indicative that the subject is at risk of developing dry AMD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is obtained from a skin biopsy or is a blood sample.

### Claim 3 (depends on 2)

The method claim 2, wherein the method comprises obtaining the skin biopsy from the subject and transforming the skin fibroblasts obtained from the skin biopsy into retinal pigment epithelial cells (RPE) prior to determining the expression or activity levels of the PGC-1α or SIRT-1 or PARP2 in the sample, or prior to determining the mRNA levels of the AKT3 in the sample.

### Claim at position 4

4-13. (canceled)

### Claim 14

A method of monitoring the progression of dry age-related macular degeneration (dry AMD) in a subject, the method comprising
a) analyzing at least two samples from the subject with each sample taken at different time points to determine expression or activity levels of at least one of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α), NAD-dependent deacetylase sirtuin-1 (SIRT-1), and Poly (Adenosine diphosphate-Ribose) Polymerase 2 (PARP2); or analyzing at least two samples from the subject with each sample taken at different time points to determine mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3), and
b) comparing the expression or activity levels of the subject's PGC-1α or SIRT-1 or PARP2 over time to determine if expression or activity levels of PGC-1α or SIRT-1 or PARP2 are changing over time; comparing the mRNA levels of the subject's AKT3 over time to determine if mRNA levels of AKT3 are changing over time,
wherein a decrease in the subject's expression or activity levels of PGC-1α or SIRT-1 over time is indicative that the subject's risk of suffering from dry AMD is increasing over time; wherein an increase in the subject's expression or activity levels of PARP2 over time is indicative that the subject's risk of suffering from dry AMD is increasing over time; and wherein a decrease in the subject's mRNA levels of AKT3 over time is indicative that the subject's risk of suffering from dry AMD is increasing over time.

### Claim at position 6

15-25. (canceled)

### Claim 26

A method of reversing symptoms of dry age-related macular degeneration (dry AMD) in a subject in need of treatment thereof, the method comprising administering at least one of (i) a compound that induces expression or activity of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α) in retinal pigment epithelial cells; (ii) a compound that induces expression of RAC-gamma serine/threonine-protein kinase (AKT3) in retinal pigment epithelial cells; (iii) a compound that induces expression of NAD-dependent deacetylase sirtuin-1 (SIRT-1) in retinal pigment epithelial cells; and (iv) an inhibitor of Poly (Adenosine diphosphate-Ribose) Polymerase 2 (PARP2) in a therapeutically effective amount.

### Claim 27 (depends on 26)

The method of claim 26, wherein the compound that induces expression of PGC-1α is a fibrate.

### Claim 28 (depends on 27)

The method of claim 27, wherein the fibrate is selected from the group consisting of bezafibrate, ciprofibrate, clofibrate gemfibrozil, fenofibrate and clinofibrate.

### Claim 29 (depends on 26)

The method of claim 26 wherein the compound that induces expression of PGC-1α is a sartan.

### Claim 30 (depends on 29)

The method of claim 29, wherein the sartan is selected from the group consisting of losartan, telmisartan, irbesartan, azilsartan, olmesartan, valsartan, eprosartan, temposartan and candesartan.

### Claim at position 12 (depends on 26)

31-34. (canceled) (Currently amended) The method of claim 26, wherein the PARP inhibitor is administered topically.

### Claim 36 (depends on 35)

The method of claim 35, wherein the PARP inhibitor is comprised within a liquid composition.

### Claim 37 (depends on 36)

The method of claim 36, wherein the amount of PARP inhibitor that is administered to the subject is about 1 ng.

### Claim 38 (depends on 26)

The method of claim 26, further comprising determining expression or activity levels of PGC-1α in a sample obtained from the subject, and administering the compound that induces expression or activity of PGC-1α when there is a reduction in the expression or activity levels of PGC-1α in the sample compared to normal levels of PGC-1α.

### Claim 39 (depends on 38)

The method of claim 38, wherein the sample is obtained from a skin biopsy.

### Claim 40 (depends on 39)

The method claim 39, wherein the method comprises obtaining the skin biopsy from the subject and transforming the skin fibroblasts obtained from the skin biopsy into retinal pigment epithelial cells (RPE) prior to determining the expression or activity levels of the PGC-1α in the sample.
